📈 69% of S&P 500 stocks beating the index - a historic record! Pick the best ones with AI.See top stocks

Jefferies shifts IQVIA stock to 'Hold', notes booking and competitive pressures

EditorEmilio Ghigini
Published 2024/07/24, 09:34
IQV
-

On Wednesday, Jefferies adjusted its stance on IQVIA Holdings (NYSE:IQV) stock, shifting the rating from Buy to Hold and lowering the price target from $266.00 to $242.00. The modification follows observations of the company's recent performance trends.

A Jefferies representative highlighted that IQVIA's bookings increased by only approximately 0.5% in the first half of 2024, and that total trailing twelve months (TTM) bookings have seen a year-over-year decline for two consecutive quarters.

The analyst noted that a growing proportion of longer-duration studies, such as those in oncology, central nervous system (CNS), and rare diseases, have contributed to a slower burn rate.

This trend, combined with the sluggish pace of bookings, is expected to result in research and development services (R&DS) growth remaining in the mid-single digits percentage range for 2025. This forecast is below the high-single-digit percentage range that was previously implied by consensual estimates.

Further concerns were raised regarding IQVIA's data business, which is reportedly encountering heightened competition. Competitors such as Veeva Systems (NYSE:VEEV) Inc. and other firms like Symphony and Norstella are offering more rapid update times and access to data from challenging-to-reach sources, including specialty pharmacies and blocked drugs. These competitive pressures could impact IQVIA's market position.

The guidance provided by IQVIA suggests an acceleration in the second half of the year for their Technology & Analytics Solutions (TAS), but Jefferies remains cautious. The firm believes that despite a stronger performance in the second quarter, the projected acceleration appears ambitious.

IQVIA Holdings, a prominent provider of advanced analytics, technology solutions, and contract research services to the life sciences industry, will now be navigating these market conditions with a more conservative outlook from Jefferies.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.